Home » Headlines » Currently Reading:

Morning Headlines 8/14/20

August 13, 2020 Headlines No Comments

Teladoc rival MDLive is preparing to go public next year

MDLive plans to launch an IPO early next year, encouraged by Teladoc’s announced $18.5 billion acquisition of Livongo.

CancerIQ Raises $5M in VC Funding, Adds Strategic Hires to Epic Integration Team

Precision medicine software startup CancerIQ will use a new $5 million investment to further scale its oncology-focused technology, add staff members to its EHR integration team, and seek out new genomics partners.

Craneware Plans Bumper Placing As It Eyes Acquisition Opportunities

Scotland-based Craneware will raise $100 million, about 20% of its market value, to fund potential acquisitions from a small number of opportunities it has identified.

Epic Systems Reverses Course On Mandatory In-Person Work Policy

Epic makes its planned return to campus optional, reversing its previous decision and allowing employees to work from home through at least the end of the year.



HIStalk Featured Sponsors

     

Text Ads


RECENT COMMENTS

  1. "Healthcare startup Particle Health has been battling electronic health records giant Epic Systems all year. Now, the startup just raised…

  2. I'd never heard of Healwell before and took a look over their offerings. Has anyone used the products? Beyond the…

  3. Neither of those sound like good news for Oracle Health. After the lofty proclamations of the last couple years. still…

  4. I doubt much has changed with the former Cerner except that Safra stopped ripping the business after Oracle ended breaking…

  5. There was a recent report pointing to increased Medicare costs when patients returned to traditional Medicare, of course assuming that…

Founding Sponsors


 

Platinum Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold Sponsors


 

 

 

 

 

 

 

 

RSS Webinars

  • An error has occurred, which probably means the feed is down. Try again later.